Death receptors on reactive astrocytes: A key role in the fine tuning of brain inflammation?

Neurology

Volumn 60, Issue 4, 2003, Pages 548-554

  Dietrich, Pierre Yves ^a   Walker, Paul R ^a   Saas, Philippe ^b  

^a Hôpital Universitaire HUG   (Switzerland)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIMENTIN;

ALZHEIMER DISEASE; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN TUMOR; ENCEPHALITIS; GLIOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATORY CELL; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0037465548     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000042049.74547.7F     Document Type: Review

References (90)

1. Streilein JW, Taylor AW, Kosiewicz M, Takeuchi M. Peripheral T-cell tolerance and ocular immune privilege. In: Banchereau J, Dodet B, Schwartz R, Trannoy E, eds. Immune tolerance. Paris, France: Elsevier, 1996;35-45.
2. Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol 1997;9:723-729.
3. Irani DN, Griffin DE. Regulation of lymphocyte homing into the brain during viral encephalitis at various stages of infection. J Immunol 1996;156:3850-3857.
4. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-232.
5. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999;22:219-240.
6. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000;21:141-147.
7. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999;283:496-497.
8. Piani D, Frei K, Pfister HW, Fontana A. Glutamate uptake by astrocytes is inhibited by reactive oxygen intermediates but not by other macrophage-derived molecules including cytokines, leukotrienes or platelet-activating factor. J Neuroimmunol 1993;48:99-104.
9. Eddleston M, Mucke L. Molecular profile of reactive astrocytes implications for their role in neurologic disease. Neuroscience 1993;54:15-36.
10. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 1996;19:331-338.
11. Shrikant P, Benveniste EN. The central nervous system as an immunocompetent organ. Role of glial cells in antigen presentation. J Immunol 1996;157:1819-1822.
12. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol 1998;160:4271-4279.
13. Dhib-Jalbut S, Kufta CV, Flerlage M, Shimojo N, McFarland HF. Adult human glial cells can present target antigens to HLA-restricted cytotoxic T-cells. J Neuroimmunol 1990;29:203-211.
14. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol 1998;161:5959-5966.
15. Gold R, Schmied M, Tontsch U, et al. Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Brain 1996;119:651-659.
16. Kohji T, Tanuma N, Aikawa Y, et al. Interaction between apoptotic cells and reactive brain cells in the central nervous system of rats with autoimmune encephalomyelitis. J Neuroimmunol 1998;82:168-174.
17. Aloisi F, Ria F, Penna G, Adorini L. Microglia are more efficient than astrocytes in antigen processing and Th1 but not Th2 cell activation. J Immunol 1998;160:4671-4680.
18. Aloisi F, Ria F, Columba-Cabezas S, Hess H, Penna G, Adorini L. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol 1999;29:2705-2714.
19. Aloisi F, Penna G, Cerase J, Iglesias BM, Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997;159:1604-1612.
20. Horwitz MS, Evans CF, Klier FG, Oldstone MB. Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules. Lab Invest 1999;79:235-242.
21. Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia 2001;36:145-155.
22. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987;325:253-257.
23. Kakinuma Y, Hama H, Sugiyama F, et al. Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nat Med 1998;4:1078-1080.
24. Bush TG, Puvanachandra N, Horner CH, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scarforming, reactive astrocytes in adult transgenic mice. Neuron 1999;23:297-308.
25. de Boer AG, Breimer DD. Cytokines and blood-brain barrier permeability. Prog Brain Res 1998;115:425-451.
26. Weiss JM, Downie SA, Lyman WD, Berman JW. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J Immunol 1999;161:6893-6903.
27. Mucke L, Eddleston M. Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J 1993;7:1226-1232.
28. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997;20:570-577.
29. Aloisi F, Borsellino G, Care A, et al. Cytokine regulation of astrocyte function: in-vitro studies using cells from the human brain. Int J Dev Neurosci 1995;13:265-274.
30. Wu VW, Schwartz JP. Cell culture models for reactive gliosis: new perspectives. J Neurosci Res 1998;51:675-681.
31. Aloisi F, Care A, Borsellino G, et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1β and tumor necrosis factor-α. J Immunol 1992;149:2358-2366.
32. Petito CK, Roberts B. Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 1995;146:1121-1130.
33. Li WP, Chan WY, Lai HW, Yew DT. Terminal dUTP nick end labeling (tunel) positive cells in the different regions of the brain in normal aging and Alzheimer patients. J Mol Neurosci 1997;8:75-82.
34. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1518.
35. Palma JP, Yauch RL, Lang S, Kim BS. Potential role of CD4+ T cell-mediated apoptosis of activated astrocytes in Theiler's virusinduced demyelination. J Immunol 1999;162:6543-6551.
36. Shi B, De Girolami U, He J, et al. Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest 1996;98:1979-1990.
37. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
38. Nishimura T, Akiyama H, Yonehara S, et al. Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res 1995;695:137-145.
39. Ferrer I, Puig B, Krupinsk J, Carmona M, Blanco R. Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathol (Berl) 2001;102:121-131.
40. Ferrer I, Blanco R, Cutillas B, Ambresio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol 2000;26:424-433.
41. Becher B, D'Souza SD, Troutt AB, Antel JP. Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neuroscience 1998;84:627-634.
42. Malipiero U, Frei K, Spanaus K-S, et al. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas liganddeficient lpr and gld mice. Eur J Immunol 1997;27:3151-3160.
43. Saas P, Boucraut J, Quiquerez A-L, et al. CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? J Immunol 1999;162:2326-2333.
44. Choi C, Park JY, Lee J, et al. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J Immunol 1999;162:1889-1895.
45. Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN. Differential regulation and function of Fas expression on glial cells. J Immunol 2000;164:1277-1285.
46. Leithaüser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-429.
47. Aquaro S, Panti S, Caroleo MC, et al. Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J Leukoc Biol 2000;68:429-435.
48. Tsutsui H, Kayagaki N, Kuida K, et al. Caspase-l-independent, Fas/ Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999;11:359-367.
49. Rensing-Ehl A, Hess S, Ziegler-Heitbrock HW, Riethmuller G, Engelmann H. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm 1995;45:161-174.
50. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999;5:292-297.
51. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol 1995;155:4147-4154.
52. Saas P, Boucraut J, Walker PR, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000;32:102-107.
53. Frohman EM, Frohman TC, Dustin ML, et al. The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J Neuroimmunol 1989;23:117-124.
54. Abdel-Haq N, Hao HN, Lyman WD. Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J Neuroimmunol 1999;101:7-14.
55. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
56. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827-828.
57. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
58. de Vries EGE, Van der Graaf WTA, Heijenbrok FJ, Joekstra HJ, de Jong S. Don't blaze the trailblazer TRAIL too early. Lancet 2000;356:2014.
59. Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995;54:766-775.
60. Kossmann T, Stahel PF, Lenzlinger PM, et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with bloodbrain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 1997;17:280-289.
61. Dorf ME, Berman MA, Tanabe S, Heesen M, Luo Y. Astrocytes express functional chemokine receptors. J Neuroimmunol 2000;111:109-121.
62. März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999;26:191-200.
63. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc Natl Acad Sci USA 1993;90:10061-10065.
64. Eugster HP, Frei K, Winkler F, et al. Superantigen overcomes resistance of IL-6-deficient mice towards MOG-induced EAE by a TNFR1 controlled pathway. Eur J Immunol 2001;31:2302-2312.
65. Fattori E, Lazzaro D, Musiani P, Modesti A, Alonzi T, Ciliberto G. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci 1995;7:2441-2449.
66. Chiang C-S, Stalder AK, Samimi A, Campbell IL. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev Neurosci 1994;16:212-221.
67. Tilgner J, Volk B, Kaltschmidt C. Continuous interleukin-6 application in vivo via macroencapsulation of interleukin-6-expressing COS-7 cells induces massive gliosis. Glia 2001;35:234-245.
68. Ferrero E, Fabbri M, Poggi A, Galati G, Bernasconi S, Zocchi MR. Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the alpha1 integrin I-domain. Eur J Immunol 1998;28:2530-2536.
69. Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;186:1201-1212.
70. Araujo DM, Cotman CW. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res 1993;600:49-55.
71. Bruno V, Copani A, Besong G, Scoto G, Nicoletti F. Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloidinduced toxicity in culture. Eur J Pharmacol 2000;399:117-121.
72. Adamson P, Etienne S, Couraud PO, Calder V, Greenwood J. Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway. J Immunol 1999;162:2964-2973.
73. Matsumoto Y, Ohmori K, Fujiwara M. Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system. J Neuroimmunol 1992;37:23-33.
74. Borrow P, Cornell JL, Ruppe MD, Mucke L. Immunization-induced inflammatory infiltration of the central nervous system in transgenic mice expressing a microbial antigen in astrocytes. J Neuroimmunol 1995;61:133-149.
75. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999;27:62-74.
76. Flugel A, Schwaiger FW, Neumann H, et al. Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol 2000;10:353-364.
77. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000;192:1373-1380.
78. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-1354.
79. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-1460.
80. Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNFrelated apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639-2647.
81. Probert L, Akassoglou K. Glial expression of tumor necrosis factor in transgenic animals: how do these models reflect the "normal situation"? Glia 2001;36:212-219.
82. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 2000;21:110-113.
83. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF-alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4:1116-1122.
84. Saas P, Walker PR, Quiquerez AL, et al. A self-defense mechanism of astrocytes to Fas mediated death involving IL-8 and CXCR2. Neuro-Report 2002;13:1921-1924.
85. Cota M, Kleinschmidt A, Ceccherini-Silberstein F, et al. Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. J Neurovirol 2000;6:75-83.
86. Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med 1997;185:2039-2041.
87. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G. TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997;72:137-141.
88. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998;10:669-676.
89. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5:1256-1263.
90. Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med 2002;8:199-200.